Got $3,000? Here Are 3 Best Warren Buffett Stocks to Buy
Warren Buffett’s portfolio at Berkshire Hathaway has been an excellent source of ideas for generations of investors. Even though the Oracle of Omaha is pulling back to cash heavily this year, there are still some fantastic stocks being held at Berkshire that appear undervalued and bear watching.
Here are three of the best Buffett stocks to look into if you have a few thousand dollars to put to work in today’s market. » Read more about: Got $3,000? Here Are 3 Best Warren Buffett Stocks to Buy »
Read More
Alert: 34.5% Upside in Under the Radar Global Stock
Investment Alert: Buy Celestica (CLS) Under $30/share
Disclaimer: Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
» Read more about: Alert: 34.5% Upside in Under the Radar Global Stock »
Read More
Alert: 40.6% Upside In High Dividend Footwear Firm
Investment Alert: Buy Weyco (WEYS) Under $26/share
Disclaimer: Investment Alerts have a medium to long-term time horizon. These do not constitute financial advice and you should contact a financial advisor before deciding whether it is appropriate for your individual circumstances.
Weyco Group is a footwear company that designs,
» Read more about: Alert: 40.6% Upside In High Dividend Footwear Firm »
Read More
Market Commentary: 1 Stock Has Popped 80% Of The Time
Dick’s Sporting Goods has lots going for it. It’s a well-known brand with a trusted customer base, and its sales have been on the rise the past few years, up 28.3% in 2022 alone before slowing down in 2023.
It’s also got a pretty attractive dividend, paying out 2.7% to loyal shareholders. And at an 11.7x P/E ratio the company is not trading at a particularly lofty multiple.
» Read more about: Market Commentary: 1 Stock Has Popped 80% Of The Time »
Read More
Is Your Favorite Pharmacy About To Go Belly Up?
Walgreens Boots Alliance stands at a critical juncture in the company’s 170-year history with revenues of $147 billion but a market capitalization of just $7 billion.
A heavily burdened balance sheet has been the prime culprit of the stock’s downfall but, under new CEO Tim Wentworth, management is undertaking an ambitious realignment aimed at stabilizing the core pharmacy business while taking the chop to some of its healthcare investments.
» Read more about: Is Your Favorite Pharmacy About To Go Belly Up? »
Read MoreThe Burst
Why Coinbase Could Soar
Among the best business models in the world is the money management one. While fees have come down substantially in recent decades, you can certainly still find examples of financial advisors charging north of 1% on assets under management while another 1% is charged through commissions, 10b-1 fees, and mutual fund costs.
Sum those up and 2% of invested capital is lost each year to these hefty fees.
» Read more about: Why Coinbase Could Soar »
Read MoreThe Spotlight
Spotlight: 1 Gene Editing Stock Set To Skyrocket
Cathie Wood has been investing heavily in Verve Therapeutics (VERV), a company developing therapies for cardiovascular diseases. So what’s all the fuss about? We took a deeper dive to find out.
Read MoreThe Daily
Stock Market Live July 22: S&P 500 (VOO) Inches Higher Despite Mixed Earnings News
Investing
-
Bloomberg reports that Google is recruiting news agencies to join a new AI project.